Discontinuing psychotropic drug treatment
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Summary: Interruption of ongoing treatment with benzodiazepines, antidepressants, antipsychotics and mood stabilisers including lithium can be followed by clinically significant withdrawal reactions within hours or days, as well as later increases in relapses or recurrences of the illness being treated. Such observations support the view that stopping treatment is not equivalent to being untreated. With lithium, antipsychotics and antidepressants, there is consistent evidence that abrupt or rapid discontinuation is followed by earlier clinical worsening than with more gradual removal of treatment. Moreover, treatment discontinuation can complicate interpretation of responses to changes in treatment, including in clinical practice and in experimental treatment trials. Notably, terminating preceding treatments can lead to both discontinuation and carry-over effects that can have an impact on the interpretation of observed outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viguera, A. C., Whitfield, T., Baldessarini, R. J., Newport, D. J., Stowe, Z., Reminick, A., Zurick, A., & Cohen, L. S. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06101639 · Cited by 599
Self-citationViguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.179 · Cited by 488
Self-citationBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · cited 1×
“17 Pregnancy is commonly associated with interruption of ongoing medicinal treatments – often abruptly, typically driven by fear of teratogenic or toxic effects on the fetus and associated liability.”
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Outcome After Rapid vs Gradual Discontinuation of Lithium Treatment in Bipolar Disorders
Faedda, G. L. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180046005 · Cited by 239
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317753340 · Cited by 109 · cited 1×
“Early withdrawal reactions commonly follow discontinuation of benzodiazepines 2 as well as some antidepressants, particularly selective serotonin reuptake inhibitors.”
Cited by
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954609 · Cited by 35
(2024) · doi:10.1016/j.psychres.2024.115926 · Cited by 15
Using psychopharmacology in the treatment of problem behaviours in dogs and cats
Warnes, C. E. (2021) · Companion Animal · doi:10.12968/coan.2021.0032 · Cited by 4
Metadata
- Authors
- Tondo, L., & Baldessarini, R. J.
- Venue
- BJPsych Open
- Publisher
- Royal College of Psychiatrists
- Published
- 2020-02-19
- Volume
- 6
- Issue
- 2
- Pages
- e24-e24
- ISSN
- 2056-4724 (ISSN-L)
- OpenAlex
- W3007584427
- Cited by
- 27
- References
- 16
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.